ArticleClinica chimica acta; international journal of clinical chemistry2021
ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors.
Article in Clinica chimica acta; international journal of clinical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 7 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Pooled it
- Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Pooled it
- Pooled it
- Genetics of COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review.Annals of clinical and translational neurology · 2022Pooled it
- Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis.Microbial pathogenesis · 2022Pooled it
- Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Pooled it
- Surfactant-Associated Protein D Polymorphism and Protection Against COVID-19 in the Czech Population.Immunity, inflammation and disease · 2026Article
- The Effect of Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Severity and Death Rate of COVID-19 in Iranian Patients.Biochemical genetics · 2024Article
- Association of genetic polymorphisms with COVID-19 infection and outcomes: An updated meta-analysis based on 62 studies.Heliyon · 2024Article
- Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients.BMC research notes · 2023Article
- ABCA3 and LZTFL1 Polymorphisms and Risk of COVID-19 in the Czech Population.Physiological research · 2023Article
- Strong association between angiotensin-converting enzyme gene InDel polymorphism and COVID-19 diseases.Medicina clinica (English ed.) · 2023Article
- Reductionist methodology and the ambiguity of the categories of race and ethnicity in biomedical research: an exploratory study of recent evidence.Medicine, health care, and philosophy · 2023Article
- Single Nucleotide Variants (SNVs) of Angiotensin-Converting Enzymes (ACE1 and ACE2): A Plausible Explanation for the Global Variation in COVID-19 Prevalence.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Review
- Association investigations between ACE1 and ACE2 polymorphisms and severity of COVID-19 disease.Molecular genetics and genomics : MGG · 2023Article
- Polymorphisms inGenes · 2022Article
- The association of ACE I/D polymorphism with the severity of COVID-19 in Iranian patients: A case-control study.Human gene (Amsterdam, Netherlands) · 2022Article
- Article
- Viral and Host Genetic and Epigenetic Biomarkers Related to SARS-CoV-2 Cell Entry, Infection Rate, and Disease Severity.Biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality.
methodsIn our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects.
resultsThe frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76).
conclusionsWe conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID-19, with I/I homozygotes being at increased risk of symptomatic COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.